Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Tiziana Life Sciences ( (TLSA) ) has issued an update.
On January 22, 2025, Tiziana Life Sciences announced the discovery of new immune biomarkers in patients with non-active secondary progressive multiple sclerosis (na-SPMS) treated with nasal foralumab. The study, which began in November 2023, revealed significant gene expression changes associated with immune modulation, underscoring the potential of nasal foralumab in personalizing treatment strategies for MS and other neurodegenerative diseases. These findings enhance the understanding of the drug’s mechanism, paving the way for future trials and clinical exploration.
More about Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company focused on developing breakthrough therapies through innovative drug delivery technologies. Their lead candidate, intranasal foralumab, is a fully human anti-CD3 monoclonal antibody that aims to improve the safety and efficacy of immunotherapy.
YTD Price Performance: 7.94%
Average Trading Volume: 382,423
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $81.27M
For an in-depth examination of TLSA stock, go to TipRanks’ Stock Analysis page.
